Cancer Antigen 15-3 (CA-15-3)
Cancer Antigen 15-3 a mucin involved in cell adhesion is over-expressed and aberrantly glycosylated in various cancers and is used to detect recurrence and monitor treatment in breast cancer patients. Evidence exists that CA 15-3 is over-expressed to a greater extent than CA-125 in all subtypes of ovarian cancer. High levels are associated with breast, ovarian, prostate and lung cancers as well as non-cancerous ovarian disease.
Swiss-Prot Accession Number: P15941
TGFb receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer (2019) Melisi D, Garcia-Carbonero R, Macarulla T, Pezet D, Deplangue G, Fuchs M, Trojan J, Kozloff M, Simionato F, Cleverly A, Smith C, Wang S, Man M, Driscoll KE, Estrem ST, Lahn MMF, Benhadji KA, Tabernero J Cancer Chemotherapy and Pharmacology
Phase Ib Study of Glasdegib, A Hedgehog Pathway Inhibitor, in (2018) Savona M, Pollyea D, Stock W, Oehler V, Schroeder MA, Lancet J, McCloskey J, Kantarigian H, Ma WW, Shaik MN, Laird AD, Zeremski M, O'Connell A, Chan G, Cortes JE Clinical Cancer Research
Dendritic cell immunotherapy followed by cART interruption during HIV-1 infection induces plasma protein markers of cellular immunity and neutrophil recruitment (2018) van den Ham HJ, Cooper J, Tomasik J, Bahn S, Aerts J, Oseterhaus A, Gruters R, Andeweg A PLoS One
Circulating Biomarkers and Outcome from a Randomised Phase Ii Trial of Sunitinib Vs Everolimus for Patients with Metastatic Renal Cell Carcinoma (2016) Voss MH, Chen D, Marker M, Hakimi AA, Lee C-H, Hsieh JJ, Knox JJ, Voi M, Motzer RJ British Journal of Cancer
Variation in Serum Biomarkers with Sex and Female Hormonal Status: Implications for Clinical Tests (2016) Ramsey JM, Cooper JD, Penninx BWJH, Bahn S Scientific Reports